Physician profile
James Logothetis
NPI 1740279124
$7,601.14
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,379 · 2020: $2,532 · 2021: $1,605 · 2022: $85.05.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,259.86 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $990.94 | 2019-2021 | |
| Amgen INC. | $976.74 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $668.04 | 2019-2021 | |
| Glaxosmithkline, LLC. | $640.53 | 2019-2021 | |
| Astellas Pharma US INC | $320.22 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $235.57 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $229.45 | 2019-2021 | |
| Novo Nordisk INC | $221.37 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $205.72 | 2019-2021 | |
| Allergan, INC. | $200.68 | 2019-2020 | |
| Abbvie INC. | $162.17 | 2021 | |
| Esperion Therapeutics, INC. | $154.75 | 2020-2021 | |
| Lilly USA, LLC | $150.03 | 2019-2021 | |
| Gilead Sciences, INC. | $130.26 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $129.80 | 2019-2021 | |
| Mannkind Corporation | $128.70 | 2019-2021 | |
| Amarin Pharma, INC. | $105.39 | 2019-2020 | |
| Mylan Specialty L.P. | $105.37 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $67.03 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $66.51 | 2019-2021 | |
| Electromed, INC. | $42.54 | 2019-2021 | |
| Shire North American Group INC | $42.27 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $42.25 | 2019 | |
| Avanir Pharmaceuticals, INC. | $42.16 | 2019 | |
| Genentech USA, INC. | $39.61 | 2019 | |
| Philips North America LLC | $38.20 | 2019-2020 | |
| Circassia INC. | $28.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $25.51 | 2019-2021 | |
| Genzyme Corporation | $23.77 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.49 | 2021 | |
| Sanofi Pasteur INC. | $13.38 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.23 | 2021 | |
| Hikma Pharmaceuticals USA | $12.35 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.35 | 2021 | |
| Currax Pharmaceuticals LLC | $12.02 | 2021 | |
| Eisai INC. | $11.83 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Logothetis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.